Morgan Stanley raised the firm’s price target on Crispr Therapeutics (CRSP) to $33 from $32 and keeps an Underweight rating on the shares. The firm refreshed its Crispr estimates and reviewed incremental pipeline progress after partner Vertex Pharmaceuticals (VRTX) recently reported Q4 Casgevy sales.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- IHI, IHE, ARKG: Specialty Healthcare ETFs Can Help Boost a Portfolio
- Crispr Therapeutics price target lowered to $67 from $69 at JPMorgan
- Crispr Therapeutics price target raised to $80 from $77 at Citi
- CRISPR Therapeutics: Casgevy Outperformance and 2026 Pipeline Catalysts Drive Raised $80 Target and Buy, High Risk Rating
- Crispr Therapeutics price target raised to $76 from $74 at Chardan